Thermo Fisher Scientific Inc., the
world leader in serving science, today announced that it has enhanced its
workflow for biomarker research and diagnostics by acquiring Intrinsic
Bioprobes Inc., a manufacturer of unique immuno-enrichment, sample-preparation
tools used in quantitative mass spectrometry. The Intrinsic Bioprobes portfolio enables Thermo Fisher to offer its
worldwide life science research and clinical diagnostics customers an enhanced solution for quantitative protein
biomarker detection.
The Intrinsic Bioprobes portfolio includes
its novel Mass Spectrometric Immunoassay (MSIA
TM),
featuring a patented sample preparation technique. This technology allows
enrichment of low-abundance proteins in biological samples. The specificity of
immuno-enrichment, coupled with the sensitivity and quantitative capability of
mass spectrometry, is a powerful tool, giving researchers a complete, higher-resolution
view of the proteome. Furthermore, the MSIA technology offers clear advantages
over conventional ELISA and bead-based immunoassay formats, providing greater
sensitivity and higher throughput.
Adding Intrinsic Bioprobes' consumable
sample-preparation technologies to Thermo Fisher's automated sample processing
and quantitative mass spectrometry instruments and software creates a complete,
integrated workflow for the quantitative detection of protein biomarkers.
"The Intrinsic Bioprobes portfolio will
enhance Thermo Fisher's position in the rapidly emerging field of clinical
proteomics," said Chuck Kummeth, president of Thermo Fisher's, laboratory consumables
business. "It is a simple, yet powerful approach to uncovering the proteomic
basis of disease, and it better positions us to support our customers in their
efforts to realize the promise of personalized medicine."
Intrinsic Bioprobes was founded by in
1996 by Randall W. Nelson, who has served as its president since then. He will
continue to be involved with the business as a consultant.
For more information visit
www.thermofisher.com.
